Streetbeat News

Regulatory

HOOD

PYPL

Robinhood and Revolut are reportedly considering launching their own stablecoins, potentially challenging Tether's dominance in the $170 billion market. This move comes as the EU prepares to implement new crypto regulations, which could impact Tether's operations. Meanwhile, PayPal is expanding its crypto offerings.

Portfolio Pulse from Ivan Crnogatić

September 26, 2024 | 8:11 pm

CRNX

Crinetics Pharmaceuticals has submitted a New Drug Application to the FDA for paltusotine, a novel treatment for acromegaly. This marks a significant step for the company in advancing its drug pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 8:10 pm

QGEN

QIAGEN has received European IVDR certification for its QIAstat-Dx syndromic testing instruments and assays, marking a significant regulatory milestone. This certification allows QIAGEN to continue marketing these products in Europe, potentially boosting their market presence and sales.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 8:10 pm

WLDS

Wearable Devices has filed a patent application with the Korean Intellectual Property Office for a gesture and voice-controlled interface device. This move is part of their strategy to expand global protection of their core intellectual property.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 8:05 pm

TVTX

Travere Therapeutics has voluntarily paused enrollment in its Phase 3 HARMONY study of Pegtibatinase to address necessary process improvements in manufacturing scale-up. This pause is intended to support commercial scale manufacturing and full enrollment in the study.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 8:02 pm

ALLR

Allarity Therapeutics has been granted a European patent for methods predicting drug responsiveness in cancer patients. This development could enhance their drug development process and potentially improve treatment outcomes.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 7:59 pm

PFE

The FDA has announced a voluntary withdrawal of Oxbryta from the market due to safety concerns. This decision impacts patients and healthcare professionals who use or prescribe this medication.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 7:27 pm

ACHC

Acadia Healthcare Company has agreed to pay $19.85 million to settle allegations of billing for medically unnecessary inpatient behavioral health services. The settlement resolves claims under the False Claims Act and related state statutes, with $16.66 million going to the U.S. government and $3.18 million to four states. The allegations include improper admissions, excessive lengths of stay, and inadequate staffing, leading to patient harm.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 7:10 pm

ACHC

Acadia Healthcare Company has agreed to pay $19.85 million to settle allegations of billing for medically unnecessary inpatient behavioral health services. The settlement resolves claims under the False Claims Act and related state statutes, with payments to both the federal government and several states.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 7:08 pm

SPY

The upcoming PCE price index report is crucial for validating the Federal Reserve's recent interest rate cuts and predicting future cuts. Market experts expect a slight decrease in headline PCE inflation and a slight increase in core PCE inflation. The SPDR S&P 500 ETF Trust (SPY) has been trading higher ahead of the report.

Portfolio Pulse from Chris Katje

September 26, 2024 | 6:58 pm